Urologist Dean Tortorelis, MD, FACS Treats 100th Patient with the UroLift® System for Enlarged Prostate

Share Article

Performs the Most UroLift System Treatments in Minnesota

Dr. Dean Tortorelis of MN Urology announced that his 100th patient has been treated with the UroLift® System, a proven, minimally invasive technology to treat men suffering from symptoms associated with Benign Prostatic Hyperplasia, or BPH.

“The UroLift System preserves sexual function which is important to men and their partners,” says Dr. Tortorelis “Patients like that they can have the treatment done in my office, in under an hour, with local anesthesia and/or Nitrous sedation. And best of all, they experience rapid symptom relief and return to normal routines quickly,” he adds.

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring additional treatment for relief. A second randomized clinical trial called BPH, demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System

NeoTract’s FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the treatment. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

Minnesota Urology is the largest private urology practice in the upper Midwest with more than 50 exceptional physicians and advanced level providers.
Minnesota Urology was formed as an integration of Minnesota’s two most respected independent urology practices; Urology Associates and Metro Urology. Our providers are devoted to a singular vision to deliver optimal and compassionate, patient-centered care for all adult urologic conditions.

To schedule a consultation with Dr. Tortorelis, please call 763-520-7700

# # #

Media Contact:
Amy Cramer
(650) 391-3714
amy@healthandcommerce.com

1 Roehrborn et al. EAU Abstract_ Eur Urol Suppl 2017; 16(3):e192.
2 Sonksen et al J Urology 2016
MAC00359-01 RevB

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dean Tortorelis
@UroDocDean
since: 11/2014
Follow >
Visit website